Bradley E. Kosiba, PhD, CPIP, owner of BK Collaborative, LLC, consults in Vaccine and Biotech process and facilities. His areas of special interest are Glyconconjugate vaccine development and developing realistic options for moving from batch to continuous modes of bioprocessing. Dr. Kosiba has 30 years of experience in biopharmaceuticals including vaccine development as well as design and operation of R&D and GMP facilities at Praxis Biologics, Lederle, Wyeth and Pfizer. In assignments from leading elements of early HibTITER® and Prevnar® vaccine development to leading the Wyeth response to consent decree closure of key R&D GMP facilities to leading Wyeth Global R&D’s capital strategy and engineering group, Dr. Kosiba has gained broad experience in the GMP Bioprocess arena. As a key member of the Prevnar® vaccine development leadership team, he was awarded the ACS Heroes of Chemistry for leading early Prevnar vaccine development. Dr. Kosiba received his PhD in Biochemistry from Brandeis University and a BA in Biology from Wesleyan University. He is a member of the International Society of Pharmaceutical Engineers and the American Chemical Society. He received his Certified Pharmaceutical Industry Professional (CPIP) credential in 2012 from ISPE.